论文部分内容阅读
目的观察福辛普利联合硝苯地平控释片治疗高血压合并糖尿病患者的临床疗效。方法将60例高血压合并糖尿病患者随机分为两组,常规治疗组(对照组)30例,应用硝苯地平控释片30mg/d,治疗2周;福辛普利治疗组30例,用福辛普利10～20mg/d+硝苯地平控释片30mg/d,治疗2周,观察血压控制情况,并观察其对24h尿蛋白定量、心率、血清肌酐定量的影响。结果福辛普利治疗组在降低血压的同时,明显减少24h尿蛋白的排泄,而两组治疗前后心率、血清肌酐定量无明显变化。结论福辛普利联合硝苯地平控释片在取得较理想降压效果的同时,明显减少24h尿蛋白的排泄,而对心率、血清肌酐定量无明显影响。
Objective To observe the clinical efficacy of fosinopril combined with nifedipine in the treatment of patients with hypertension and diabetes mellitus. Methods Sixty patients with hypertension and diabetes mellitus were randomly divided into two groups, 30 patients in the conventional treatment group (control group) and 30mg / d were treated with nifedipine controlled release tablets for 2 weeks, and 30 patients in the fosinopril treatment group were treated with Fosinopril 10 ~ 20mg / d + nifedipine controlled release tablets 30mg / d, for 2 weeks, observe the blood pressure control, and observe its 24 h urinary protein, heart rate, serum creatinine quantitative. Results Fosinopril treatment group decreased blood pressure at the same time, significantly reduce 24 h urinary protein excretion, while the two groups before and after treatment, heart rate, serum creatinine quantitative no significant change. Conclusions Fosinopril combined with nifedipine controlled release tablets can achieve a more ideal antihypertensive effect and significantly reduce excretion of 24-hour urinary protein, but no significant effect on heart rate and serum creatinine.